Synta Pharmaceuticals Announces FDA Fast Track Designation for STA-4783 in Metastatic Melanoma-- Designation Follows Announcement of Positive Phase 2b Clinical Data for Novel Compound -- LEXINGTON, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results